PARP1 and melanoma: In light of the potential for PARP1 inhibitors as therapeutics in melanoma [34,35,36,37,38,39,40], and the striking depletion of cellular PARP1 observed following 2HF treatment, we considered the possibility that 2HF could modulate the sensitivity of melanoma to PARP1 inhibitors.